The combined study of immune checkpoint proteins (PD-1 and PD-L1) and B lymphocytes further revealed a plausible positive predictive synergy in using CD20+ TILs and PD-L1+ tumour cells in selecting patients for neoadjuvant treatment [34]. The gene discussed is CD274; the disease is neoplasm.